DCM
CNST

DAFNA Capital Management’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

DAFNA Capital Management’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-100,594
Closed -$2.9M – 92
2020
Q4 		$2.9M Sell
100,594
-80,348
-44% -$2.02M 0.86% 28
2020
Q3 		$3.67M Buy
180,942
+10,000
+6% +$244K 1.19% 22
2020
Q2 		$5.14M Buy
+170,942
New +$6.16M 1.48% 22

Other funds holding CNST

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

DAFNA Capital Management's CNST Position: Q1 2021 in Review

DAFNA Capital Management sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q1 2021, closing a stake of 100,594 shares — an estimated $2.9M sold.

DAFNA Capital Management first reported a position in CNST in Q2 2020 and held it in 3 quarters. The position peaked at $5.14M in Q2 2020. 131 funds tracked by Wall St. Rank hold CNST as of Q1 2021.

  • DAFNA Capital Management reported no remaining Constellation Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • DAFNA Capital Management sold 100,594 Constellation Pharmaceuticals, Inc. shares in Q1 2021, an estimated $2.9M.
  • DAFNA Capital Management first reported a position in Constellation Pharmaceuticals, Inc. in Q2 2020 and held it in 3 quarters.
  • DAFNA Capital Management's Constellation Pharmaceuticals, Inc. position peaked at $5.14M in Q2 2020.
  • 131 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q1 2021.

Based on DAFNA Capital Management's 13F filing for Q1 2021, filed 17 May 2021.